trial

Glutamate Reducing Interventions in Schizophrenia

NCTId NCT03321617
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 16 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2020-03-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-04-17
Primary completion
2020-03-13
Eligibility
ALL · 18 Years · 30 Years

Interventions & indications

Drugs
Pomaglumetad

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Scott Small, MDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2020-03-13
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Clinical High Risk for Psychosis
indication
investigator
Scott Small, MD
person